NCT06322108进行中（未招募）2 期
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Immune Oncology Research Institute2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2024年6月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- 12-Month Progression-Free Survival (PFS)
研究概览
简要总结
The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.
详细描述
This is a single-arm, open-label phase II study to evaluate the safety and efficacy of the combination of botensilimab and balstilimab in participants with metastatic non-small cell lung cancer (NSCLC). The study will enroll participants with a histologically confirmed diagnosis of metastatic NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain metastases or oligometastatic disease lacking targetable lesions.
The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods:
- Screening Period: approximately 28 days
- Treatment Period: up to 24 months, or until any criterion for stopping the study drug or withdrawal from the study occurs
- Follow-up Period: up to 24 months from last dose of study treatment for every patient who is alive
Study Duration
- Recruitment: 2 years
- Treatment: 2 years
- Follow-up: 2 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically and IHC confirmed diagnosis of metastatic NSCLC which has not received any prior anticancer medicinal therapy for metastatic disease.
- •Negative for actionable EGFR mutations and ALK rearrangements.
- •Patients with recurrence after prior neoadjuvant or adjuvant chemotherapy or radiation therapy or immune checkpoint inhibitors for non-metastatic disease are eligible if recurrence occurred >6 months after the end of neoadjuvant or adjuvant treatment.
- •Documented informed consent of the participant and/or legally authorized representative
- •≥ 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥ 3 months.
- •Patients should have measurable metastatic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST guidelines.
- •Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 7 days prior to day 1 of protocol therapy) (except subjects with Gilbert syndrome who must have a total bilirubin level of ≤3.0 × ULN).
- •Aspartate aminotransferase (AST) ≤ 2.5 x ULN, unless presence of liver metastases for which ≤ 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).
- •Alanine aminotransferase (ALT) ≤ 2.5 x ULN, unless presence of liver metastases for which ≤ 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).
- •Creatinine clearance ≥ 45 ml/min (within 7 days prior to day 1 of protocol therapy).
- •Alkaline phosphatase ≤ 3 x ULN (within 7 days prior to day 1 of protocol therapy).
- •Hemoglobin ≥ 9 g/dl (within 7 days prior to day 1 of protocol therapy).
- •Absolute neutrophil count (ANC) ≥ 1500/ul (within 7 days prior to day 1 of protocol therapy).
- •Platelets ≥ 100,000/mm^3 (within 7 days prior to day 1 of protocol therapy).
- •Albumin ≥ 3.0 g/dl (within 7 days prior to day 1 of protocol therapy).
- •Women of childbearing potential (WOCBP): negative serum pregnancy test (within 7 days prior to day 1 of protocol therapy)
- •a) Females of non-childbearing potential are defined as: i. ≥ 50 years of age and has not had menses for greater than 1 year ii. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation iii. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
- •Male and female patients of reproductive potential must use effective methods of contraception (defined in Appendix A) or abstain from sexual activity for the course of the study through at least 90 days after the last dose of balstilimab and/or botensilimab
- •Is willing and able to comply with the requirements of the protocol.
排除标准
- •Prior treatment with anti-CTLA-4 and anti-PD-(L)1 therapy. Note: Prior treatment with anti-PD-(L)1 therapy in the adjuvant setting is permitted if recurrence occurred >6 months after the end of adjuvant treatment.
- •Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •Prior allogeneic organ transplantation.
- •Surgical intervention within 4 weeks prior to study treatment, except for minor procedures such as port placement.
- •Prior allergic reaction or hypersensitivity to any of the study drug components.
- •Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment, i.e., with use of disease-modifying agents or immunosuppressive drugs.
- •Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), serious uncontrolled cardiac arrhythmia requiring medication.
- •a. QTcF (QTc interval corrected using Fridericia's formula) of > 480 ms.
- •Any persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] grade ≥ 2) from prior cancer therapy, excluding endocrinopathies stable on medication, stable neuropathy that is grade 2 or less, and alopecia.
- •Active brain metastases or leptomeningeal metastases with the following exceptions:
- •a. Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. Whole-brain radiation is not allowed. Subjects must have also discontinued steroid treatment 28 days prior to enrollment for the purpose of managing their brain metastases and they must be asymptomatic and radiologically stable ≥28 days before enrollment.
- •Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 730 days (or 2 years) prior to enrollment, i.e., subjects with a history of prior malignancy are eligible if treatment was completed at least 730 days (or 2 years) before enrollment and the subject has no evidence of disease. Subjects with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
- •Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
- •Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- •History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine or booster < 7 days before C1D
- •For vaccines requiring more than 1 dose, the full series should be completed prior to C1D1, when feasible. Booster shot not required but also must be administered > 7 days from C1D1 or > 7 days from future cycle on study.
- •Uncontrolled infection with human Immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
- •Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Subjects who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 180 days prior to enrollment are eligible. Serological testing for HBV at screening is not required.
- •Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Subjects on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 180 days prior to enrollment. Serological testing for HCV at screening is not required.
- •Known active tuberculosis. Tuberculosis testing at screening is required.
- •Grade 3 or above neuropathy at the time of enrollment.
- •Dependence on total parenteral nutrition or intravenous hydration.
- •Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
- •Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
研究组 & 干预措施
Botensilimab + Balstilimab
Experimental
botensilimab 75 mg IV every 6 weeks (up to 4 doses) + balstilimab 240 mg IV every 2 weeks
干预措施: Botensilimab + Balstilimab (Drug)
结局指标
主要结局
12-Month Progression-Free Survival (PFS)
时间窗: First dose to up to 12 months
12-Month PFS is defined as the proportion of patients who remain alive and progression-free at 12 months from the first dose of investigational drug, where tumor progression is documented per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) as assessed by investigator.
次要结局
- Health-related quality of life (HRQoL) according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)(First dose to up to 25 months)
- Health-related quality of life according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC29)(First dose to up to 25 months)
- Health-related quality of life according to the 5 Level EuroQol 5 Dimension (EQ-5D-5L) questionnaire(First dose to up to 25 months)
- Disease Control Rate (DCR)(First dose to up to 6 months)
- Duration of Response (DOR)(First dose to up to 48 months)
- Time to Next Treatment (TTNT)(First dose to up to 48 months)
- Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and 12-month progression-free survival(First dose to up to 24 months)
- Correlation between existence of liver metastases on imaging at baseline and 12-month progression-free survival(First dose to up to 24 months)
- Objective Response Rate (ORR)(First dose to up to 6 months)
- Frequency, severity, and duration of treatment emergent adverse events (TEAEs) (Safety and tolerability)(First dose to up to 27 months)
- Overall Survival (OS) Time(First dose to up to 48 months)
- Correlation between existence of liver metastases on imaging at baseline and objective response rate(First dose to up to 24 months)
- Level of circulating tumor DNA (ctDNA) at baseline and at different time points after start of treatment(First dose to up to 24 months)
- Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and objective response rate(First dose to up to 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)LymphomaNCT05891821Immune Oncology Research Institute20
招募中
1 期
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerNCT06336902University of Southern California15
招募中
2 期
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) PatientsRecurrent GlioblastomaNCT05638451Zhujiang Hospital30
招募中
1 期
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerNCT05318469Yuan Yuan34
撤回
2 期
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerAdvanced Colon AdenocarcinomaAdvanced Colorectal AdenocarcinomaAdvanced Rectal AdenocarcinomaMetastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8NCT06575725City of Hope Medical Center84